The leader in adaptive PCR diagnostics.

Adaptive PCR by our PANDAA technology ensures the enduring integrity of molecular diagnostics as assay redesign is not required to detect new viral variants.

Through a process called adaptation, PANDAA uniquely corrects for sequence diversity, proactively accounting for genomic variation that may arise in future viral variants.

Our Story
HIV Drug Resistance

The leader in adaptive PCR diagnostics.

Adaptive PCR by our PANDAA technology ensures the enduring integrity of molecular diagnostics as assay redesign is not required to detect new viral variants.

Through a process called adaptation, PANDAA uniquely corrects for sequence diversity, proactively accounting for genomic variation that may arise in future viral variants.

Our Story
HIV Drug Resistance

WHat we do

As a public benefit corporation, our goal is to advance infectious disease diagnostics that facilitate society's collective response to global health emergencies.

An innovative platform for target detection in highly variable genomic regions

Aldatu Biosciences has established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Our proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases.

Our pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes. 

Aldatu Biosciences has established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Our proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases.

Our pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes. 

As first-ever Marburg outbreak in Tanzania evolves, Aldatu leads the way with pan-filovirus testing for universal access.​

Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a $3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF).

Read More »

Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio

Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a $3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF).

Read More »

ACCOUNT

OUR COMPANY

RESOURCES

Facebook-f Twitter Linkedin-in

© 2023 ALDATU BIOSCIENCES 2023